Literatur
- 1
Bolli G B, Owens D R.
Insulin glargine.
Lancet.
2005;
356
443-445
- 2
Rosak C.
Insulinanaloga: Struktur, Eigenschaft und therapeutische Indikationen.
Internist.
2001;
42
1692-1699
- 3
Lam S.
Insulin glargine: a new once-daily basal insulin for the management of type 1 and
type 2 diabetes mellitus.
Heart Dis.
2003;
5
231-240
- 4
Rosenstock J, Park G, Zimmerman J.
U.S. Basal insulin glargine (HOE 901) versus NPH insulin in patients with type 1 diabetes
on multiple daily insulin regimens. U.S. Insulin Glargine (HOE 901) Type 1 Diabetes
Investigator Group.
Diabetes Care.
2000;
23
1137-1142
- 5
Luzio S D, Beck P, Owens D R.
Comparison of the subcutaneous absorption of insulin glargine (Lantus) and NPH insulin
in patients with Type 2 diabetes.
Horm Metab Res.
2003;
35
434-438
- 6
Smith L E, Shen W, Perruzzi C. et al .
Regulation of vascular endothelial growth factor-dependent retinal neovascularization
by insulin-like growth factor-1 factor.
Nat Med..
1999;
5(12)
1390-1395
- 7
Knott R M.
Insulin-like growth factor type 1 friend or foe?.
Br J Ophthalmol.
1998;
82
719-721
- 8
Danis R P, Bingaman D P.
Insulin-like growth factor-1 retinal microangiopathy in pig eyes.
Ophthalmolohy.
1997;
104
1661-1669
- 9
Ruberte J, Ayuso E, Navarro M. et al .
Increased ocular levels of IGF-1 in transgenic mice lead to diabetes-like eye disease.
J Clin Invest.
2004;
113
1149-1157
- 10
Chantelau E.
Evidence that upregulation of serum IGF-1 concentration can trigger acceleration of
diabetic retinopathy.
Br J Ophthalmol.
1998;
82
725-730
- 11
Lang G E.
Therapie der diabetischen Retinopathie mit Somatostatinanaloga.
Ophthalmologe.
2004;
101
290-293
- 12
Arzneimittelkommission der deutschen Ärzteschaft .
Glaskörper- und Retinablutungen unter Insulin Glargin.
Deutsches Ärzteblatt.
2002;
99
727
- 13
Hauner H.
Insulin gargin - das erste lang wirkende Insulinanalogon.
Deutsches Ärzteblatt.
2003;
100
2508-2513
- 14
Eye disease prevalence research group .
The prevalence of diabetic retinopahty among adults in the United states.
Arch Ophthalmol.
2004;
122
552-563
- 15
Hammes H P.
Pathophysiological mechanisms of diabetic angiopathy.
J Diabetes Complications.
2003;
17 (2 Suppl)
16-19
- 16
Diabetes Control and Complications trial (DCCT) Research group .
The effect of intensive treatment of diabetes on the development and progression of
long-term complications in insulin-dependent diabetes mellitus.
New Eng J Med.
1993;
329
977-986
- 17
Hörle S, Gruner F, Kroll P.
Epidemiologie der diabetischen Blindheit - eine Übersicht.
Klin Monatsbl Augenheilkd.
2002;
219
777-784
PD Dr. med. Carsten H. Meyer
Zentrum für Augenheilkunde, Philipps-Universität Marburg
Robert-Koch-Straße 4
35037 Marburg
Phone: 011 49/64 21/2 86 26 16
Fax: 011 49/64 21/2 86 56 78
Email: meyer_eye@yahoo.com
